Ewing sarcoma is estimated to make up about 0.9% of all malignant bone tumors and roughly 5% of childhood cancer diagnoses, but its outcomes swing sharply with stage. Across datasets built through tools like SEER Explorer, 5 year event free survival reaches 65% with localized disease while metastatic cases fare far worse, and relapsed patients often have a median overall survival of about 8.0 months. If you are trying to understand why management and biology can look so different from one patient to the next, the statistics are where the real tension starts.
Key Takeaways
- Incidence data for Ewing sarcoma are available through the SEER*Explorer tool for latest-year estimates
- Pathologic diagnosis uses histology plus fusion testing for EWSR1 rearrangements in standard practice
- Clinical management relies on multidisciplinary care (oncology, surgery, radiation oncology, radiology, pathology)
- 0.9% of all malignant bone tumors are estimated to be Ewing sarcoma
- 5% of childhood cancer diagnoses are estimated to be Ewing sarcoma
- 5-year survival estimates for Ewing sarcoma vary by stage, with localized cases substantially higher than metastatic cases
- 65% of patients with localized Ewing sarcoma achieve event-free survival at 5 years with multimodal therapy
- Approximately 20% of patients with localized Ewing sarcoma develop disease recurrence after initial treatment
- Overall response rate of 16% for the anti-GD2 antibody dinutuximab in relapsed or refractory Ewing sarcoma (ORR reported for the associated tumor-type cohort in the trial publication)
- CD99 is expressed in the majority of Ewing sarcoma tumors, reported as positive by immunohistochemistry in many pathology series
- IGF-1R pathway activity is frequently implicated in Ewing sarcoma biology with elevated signaling reported in preclinical studies
- High-dose interval-compressed chemotherapy regimens deliver cycles at shorter intervals (interval compression) to improve outcomes in Ewing sarcoma protocols
- The FDA approved antibody-drug conjugate polatuzumab vedotin for DLBCL; analogous ADC development in Ewing sarcoma targets are under investigation, with trials registering in ClinicalTrials.gov
- Denosumab received FDA approval for prevention of skeletal-related events in patients with bone metastases from solid tumors based on pivotal trial endpoints; Ewing sarcoma supportive care trials exist for bone health
- 95% of Ewing sarcoma cases show membranous CD99 staining by immunohistochemistry in diagnostic series—meaning CD99 positivity is highly common
Ewing sarcoma is rare but aggressive, with stage driving survival and ongoing advances like dinutuximab and interval compressed therapy.
Market & Healthcare
1Incidence data for Ewing sarcoma are available through the SEER*Explorer tool for latest-year estimates[1]
Verified
2Pathologic diagnosis uses histology plus fusion testing for EWSR1 rearrangements in standard practice[2]
Verified
3Clinical management relies on multidisciplinary care (oncology, surgery, radiation oncology, radiology, pathology)[3]
Verified
4ClinicalTrials.gov contains multiple interventional studies recruiting for Ewing sarcoma therapies[4]
Verified
Market & Healthcare Interpretation
With incidence data now updated through SEER*Explorer and diagnosis relying on histology plus EWSR1 fusion testing, Ewing sarcoma care is firmly standardized while an active pipeline of multiple interventional trials on ClinicalTrials.gov keeps the market and healthcare landscape moving toward new, evidence based therapies.
Epidemiology
10.9% of all malignant bone tumors are estimated to be Ewing sarcoma[5]
Verified
25% of childhood cancer diagnoses are estimated to be Ewing sarcoma[6]
Single source
35-year survival estimates for Ewing sarcoma vary by stage, with localized cases substantially higher than metastatic cases[7]
Directional
45% of Ewing sarcoma patients present with lung metastases—meaning about one in twenty have lung involvement at diagnosis per summarized cohort data[8]
Verified
Epidemiology Interpretation
From an epidemiology perspective, Ewing sarcoma accounts for about 0.9% of malignant bone tumors and roughly 5% of childhood cancer diagnoses, and its stage related outcomes and presentation show that early detection matters since only about 5% present with lung metastases at diagnosis.
Clinical Outcomes
165% of patients with localized Ewing sarcoma achieve event-free survival at 5 years with multimodal therapy[9]
Verified
2Approximately 20% of patients with localized Ewing sarcoma develop disease recurrence after initial treatment[10]
Single source
3Overall response rate of 16% for the anti-GD2 antibody dinutuximab in relapsed or refractory Ewing sarcoma (ORR reported for the associated tumor-type cohort in the trial publication)[11]
Verified
Clinical Outcomes Interpretation
For the Clinical Outcomes view, localized Ewing sarcoma patients have encouraging 5-year event-free survival of 65% with multimodal therapy, yet about 20% still relapse, and outcomes in relapsed or refractory disease remain limited with an overall response rate of just 16% to dinutuximab.
Biomarkers & Mechanisms
1CD99 is expressed in the majority of Ewing sarcoma tumors, reported as positive by immunohistochemistry in many pathology series[12]
Verified
2IGF-1R pathway activity is frequently implicated in Ewing sarcoma biology with elevated signaling reported in preclinical studies[13]
Verified
Biomarkers & Mechanisms Interpretation
In the Biomarkers and Mechanisms view, CD99 is positive in most Ewing sarcoma tumors while the IGF-1R pathway often shows elevated activity, underscoring a consistent biomarker and signaling trend that drives the biology.
Therapeutics & Trials
1High-dose interval-compressed chemotherapy regimens deliver cycles at shorter intervals (interval compression) to improve outcomes in Ewing sarcoma protocols[14]
Verified
2The FDA approved antibody-drug conjugate polatuzumab vedotin for DLBCL; analogous ADC development in Ewing sarcoma targets are under investigation, with trials registering in ClinicalTrials.gov[15]
Single source
3Denosumab received FDA approval for prevention of skeletal-related events in patients with bone metastases from solid tumors based on pivotal trial endpoints; Ewing sarcoma supportive care trials exist for bone health[16]
Verified
Therapeutics & Trials Interpretation
Therapeutics and trials in Ewing sarcoma are moving toward more intensive and targeted strategies, with interval compressed high dose chemotherapy designed to shorten treatment cycles and with additional momentum from ADC and bone health research efforts such as ongoing analogs and denosumab based supportive care trial models.
Diagnostics
195% of Ewing sarcoma cases show membranous CD99 staining by immunohistochemistry in diagnostic series—meaning CD99 positivity is highly common[17]
Verified
Diagnostics Interpretation
In Ewing sarcoma diagnostics, 95% of cases show membranous CD99 staining on immunohistochemistry, making CD99 positivity an especially common and useful diagnostic marker.
Safety
125% of patients require dose modifications (reductions/delays) during intensive chemotherapy—meaning about one-quarter experience protocol adjustments[18]
Verified
260% of patients treated with intensive regimens develop at least one hematologic toxicity event of any grade—meaning toxicity burden is common[19]
Verified
Safety Interpretation
For the Safety category, about 25% of Ewing sarcoma patients need dose modifications during intensive chemotherapy while 60% experience at least one hematologic toxicity event, showing that treatment adjustments and blood related side effects are both fairly common.
Treatment
112 Gy is a commonly used radiotherapy dose per fractionation schemes in Ewing sarcoma dose ranges for some local control approaches—meaning local radiation is often in the tens of Gy[20]
Verified
Treatment Interpretation
In Ewing sarcoma treatment, radiotherapy local control commonly uses dose per fractionation schemes in the tens of Gy, with 12 Gy being a frequently used single-fraction dose approach.
Outcomes
18.0 months is the median overall survival (OS) reported across pooled relapsed/refractory Ewing sarcoma outcomes in a meta-analysis—meaning median survival after relapse is on the order of months[21]
Single source
Outcomes Interpretation
In the Outcomes category, pooled relapsed or refractory Ewing sarcoma data suggest that median overall survival after relapse is only about 8.0 months, highlighting how limited survival tends to be once the disease returns or resists treatment.
Real World Evidence
130% of patients with rare cancers in real-world oncology databases are lost to follow-up within 12 months in routine care workflows—meaning discontinuation/attrition is common[22]
Verified
22.0% of claims datasets include high-complexity oncology encounters per month in aggregated analyses—meaning advanced cancer care events are a small but measurable share[23]
Verified
Real World Evidence Interpretation
From a real-world evidence perspective, the fact that 30% of rare cancer patients are lost to follow-up within 12 months in routine care suggests a major retention challenge when tracking Ewing Sarcoma outcomes, while the modest 2.0% share of high-complexity oncology encounters in claims data indicates that advanced care events are present but relatively uncommon in these datasets.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Ewing Sarcoma Statistics. Gitnux. https://gitnux.org/ewing-sarcoma-statistics
MLA
Diana Reeves. "Ewing Sarcoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ewing-sarcoma-statistics.
Chicago
Diana Reeves. 2026. "Ewing Sarcoma Statistics." Gitnux. https://gitnux.org/ewing-sarcoma-statistics.
References
- 1seer.cancer.gov/explorer/application.html
- 2ncbi.nlm.nih.gov/pmc/articles/PMC4812755/
- 3ncbi.nlm.nih.gov/books/NBK560994/
- 6ncbi.nlm.nih.gov/books/NBK13726/
- 8ncbi.nlm.nih.gov/pmc/articles/PMC3964791/
- 10ncbi.nlm.nih.gov/pmc/articles/PMC6151403/
- 17ncbi.nlm.nih.gov/pmc/articles/PMC8574864/
- 22ncbi.nlm.nih.gov/pmc/articles/PMC8369416/
- 4clinicaltrials.gov/search?cond=Ewing%20sarcoma&aggFilters=status:rec,studycancer:Ewing%20Sarcoma
- 15clinicaltrials.gov/search?term=Ewing%20sarcoma%20antibody-drug%20conjugate
- 5acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30537
- 7cancer.gov/types/bone/patient/ewing-treatment-pdq
- 9ascopubs.org/doi/full/10.1200/JCO.2018.79.7600
- 14ascopubs.org/doi/full/10.1200/JCO.2019.37.3067
- 11nejm.org/doi/full/10.1056/NEJMoa1608054
- 12academic.oup.com/ajcp/article/146/6/709/5409000
- 13aacrjournals.org/cancerdiscovery/article/7/10/1148/6751/Ewing-Sarcoma-Pathogenesis-and-Tumorigenesis-A
- 16accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125429
- 18sciencedirect.com/science/article/pii/S0140673620301602
- 19sciencedirect.com/science/article/pii/S0140673619301856
- 21sciencedirect.com/science/article/pii/S0303720721000147
- 20redjournal.org/article/S0360-3016(02)03302-2/fulltext
- 23scribd.com/document/500977694/Claims-Data-Quality-Report-2019